Insider buying last 90 days
No open-market insider purchases were filed for COGT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every COGT insider filing, plotted on the chart in Gekko.Open COGT in Gekko
NASDAQ: COGT
Cogent Biosciences (COGT) Stock Analysis & Forecast
Sep 28 close
$31.86−0.45 (−1.4%)
Gekko Brief
AI summaryCogent Biosciences moves this week on news that the FDA has accepted the New Drug Application for bezuclastinib, its lead candidate targeting systemic mastocytosis and GIST. Despite this regulatory milestone, commentary describes the stock as fully valued and shares have declined over the past 30 and 90 days, with one analysis noting weak near and mid-term sentiment against a longer-term positive outlook and elevated downside risk.
Shares close at $31.86, down 1.4%, sitting between the 50-day average of $36.65 and the 200-day average of $36.55, reflecting a mixed trend. The GekkoIndex reads 66.6, placing COGT in the Accumulation zone, though this reading has slipped 5 points recently. Price sits 21.6% below the Gekko Fair Value of $40.65.
The next earnings report is set for 6 November 2026, 38 days away and outside a typical 20-trading-day holding window; the prior report on 17 March 2026 showed an EPS miss versus estimate with a -3.7% reaction, and COGT has beaten estimates in 4 of the last 8 quarters, with an average absolute reaction of 8.4%. Over the last 30 days, one unusual options signal appears, with call premium of $317,062 and no put premium recorded. Seasonally, the next 20 trading days from this point have averaged +0.4% over 5 years, rising in 2 of those years. Analyst consensus among 7 firms stands at 6 buy and 1 hold, with a consensus target of $55.82.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Cogent Biosciences price vs fair value
Close $31.86200-day averageGekko Fair Value $40.65
Cogent Biosciences quick facts
- Market cap
- $5.44B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.16
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.31
- Volume
- 2.21M avg 2.04M
- 1-year return
- +139.7%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±11.4%
- 50-day average
- $36.65
- 200-day average
- $36.55
- Next earnings
- Nov 6
- Shares outstanding
- 173.5M
Cogent Biosciences swing-trade checklist
Cogent Biosciences scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $31.86 sits between the 50-day ($36.65) and 200-day ($36.55) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.6, Accumulation
Reading 66.6 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
21.6% below
Price is 21.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 38 days
Next report Nov 6, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.4% on average
From this point in the calendar, the next 20 trading days averaged +0.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cogent Biosciences stock chart and price history
Cogent Biosciences closed at $31.86 on Sep 28, 2026, +139.7% over the past year, inside a 52-week range of $13.30 to $43.73.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.1%
- 3 months
- −17.8%
- 6 months
- −11.7%
- 1 year
- +139.7%
The full COGT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open COGT in Gekko
Follow Cogent Biosciences through every session
Put COGT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track COGT in GekkoFree for 7 days. No credit card required.
About Cogent Biosciences
Cogent Biosciences develops medicines aimed at diseases caused by specific genetic mutations. Its lead candidate is a selective tyrosine kinase inhibitor designed to target the KIT D816V mutation linked to systemic mastocytosis, as well as other KIT exon 17 mutations found in patients with advanced gastrointestinal stromal tumors. This mutation-targeted drug candidate is the focus most associated with the company.
The company works under a licensing arrangement with Plexxikon Inc. that gives it the ability to research, develop, and commercialize this compound, known as bezuclastinib. Cogent Biosciences was formerly named Unum Therapeutics Inc. before it took on its present name in October 2020.
Founded in 2014, Cogent Biosciences is based in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker COGT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- cogentbio.com
Cogent Biosciences GekkoIndex: the smart money zone
Cogent Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.6, in the Accumulation zone, down 5 points over five sessions.
66.6Accumulation
Down 5 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +1.1% | +8.6% | ||
| Accumulation (current zone) | 185 | +3.4% | +7.8% | ||
| Neutral | 387 | +1.6% | +10.1% | ||
| Distribution | 59 | +4.7% | +8.0% | ||
| Selling | 7 | Too few readings yet | |||
Average COGT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the COGT price, zone by zone.Track COGT in Gekko
Is Cogent Biosciences stock overvalued? Gekko Fair Value
Cogent Biosciences trades 21.6% below Gekko Fair Value of $40.65, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cogent Biosciences shares are worth, recalculated every trading day.
$40.65
Gekko Fair Value, Sep 29, 2026
21.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open COGT in Gekko
Cogent Biosciences insider and Congress trading
No open-market insider purchases were filed for Cogent Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in COGT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for COGT, plotted on the chart in Gekko.Open COGT in Gekko
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 22, $317K in unusual premium.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold COGT.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Cogent Biosciences earnings: next date and track record
Cogent Biosciences reports on Nov 6, 2026 (38 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 6, 2026
38 days away
- EPS estimate
- −$0.57
- Revenue estimate
- $750K
4 of 8reports beat the EPS estimate
±8.4%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 17, 2026 | −$0.56 est −$0.51 | — | −3.7% |
| Nov 3, 2025 | −$0.50 est −$0.52 | — | −13.3% |
| Aug 5, 2025 | −$0.53 est −$0.55 | — | −9.0% |
| May 5, 2025 | −$0.52 est −$0.58 | — | −19.9% |
| Feb 24, 2025 | −$0.09 est −$0.58 | — | −12.6% |
| Oct 31, 2024 | −$0.64 est −$0.57 | — | −2.4% |
| Aug 6, 2024 | −$0.59 est −$0.56 | — | −5.6% |
| May 7, 2024 | −$0.62 est −$0.52 | — | +0.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cogent Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Cogent Biosciences is $55.82, +75.2% from the last close, from 7 firms rating the stock in the last 90 days.
$55.82consensus 12-month target, +75.2% from the last close
Now $31.86Avg $55.82
Low $52High $62
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | Wedbush | $55 | +72.6% |
| Sep 16 | H.C. Wainwright | $55 | +72.6% |
| Sep 15 | LifeSci Capital | $55 | +72.6% |
| Sep 15 | H.C. Wainwright | $55 | +72.6% |
| Sep 9 | J.P. Morgan | $62 | +94.6% |
+7.8%average 20-day move after past Accumulation readings
+0.4%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cogent Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Cogent Biosciences averaged +0.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 1 of 5 |
| Next 10 trading days | +0.1% | 2 of 5 |
| Next 15 trading days | +3.0% | 3 of 5 |
| Next 20 trading days | +0.4% | 2 of 5 |
| Next 30 trading days | −5.9% | 2 of 5 |
For scale, COGT’s typical 20-trading-day move in either direction is about 11.4%.
Cogent Biosciences market cap and key statistics
Cogent Biosciences’s market cap is $5.44B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $5.44B
- EPS, TTM
- −$2.16
- Gekko Fair Value
- $40.65
Trading
- Volume
- 2.21M
- Avg volume, 20 days
- 2.04M
- 52-week high
- $43.73
- 52-week low
- $13.30
- Shares outstanding
- 173.5M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -109.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.31
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±11.4%
Cogent Biosciences stock news this week
Coverage of Cogent Biosciences this week reads neutral: 1 positive, 2 neutral and 1 negative headlines.
- Why (COGT) Price Action Is Critical for Tactical TradingStock Traders Daily, Sep 25
- Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 24
- Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA AcceptanceYahoo Finance, Sep 24
- Cogent Biosciences (COGT) Stock Price, News & AnalysisStock Titan, Sep 21
Cogent Biosciences peers
Cogent Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Cogent Biosciences stock FAQ
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $5.44B at the Sep 28, 2026 close of $31.86, with 173.5M shares outstanding.
What is the Cogent Biosciences stock forecast?
The consensus analyst 12-month price target for Cogent Biosciences is $55.82, +75.2% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cogent Biosciences stock overvalued or undervalued?
On Gekko’s estimate Cogent Biosciences is undervalued: the Sep 28, 2026 close of $31.86 is 21.6% below Gekko Fair Value of $40.65. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Cogent Biosciences report earnings next?
Cogent Biosciences is expected to report on Nov 6, 2026 (38 days away). Analysts expect earnings of −$0.57 per share on revenue of $750K. Cogent Biosciences beat the earnings estimate in 4 of its last 8 reports, moving 8.4% on average across the report.
What is Cogent Biosciences’s 52-week high and low?
Cogent Biosciences’s 52-week high is $43.73 and its 52-week low is $13.30; it closed at $31.86 on Sep 28, 2026, +139.7% over the past year.
Is Cogent Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Cogent Biosciences?
Gekko flagged 1 unusual options signal in Cogent Biosciences over the last 30 days, with $317K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 22, 2026 with $317K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cogent Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.